436 related articles for article (PubMed ID: 30479199)
1. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
Shaw DL; Dhruva SS; Ross JS
J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
[TBL] [Abstract][Full Text] [Related]
3. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
[TBL] [Abstract][Full Text] [Related]
4. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
Gupta R; Dhruva SS; Fox ER; Ross JS
J Manag Care Spec Pharm; 2017 Oct; 23(10):1066-1076. PubMed ID: 28944731
[TBL] [Abstract][Full Text] [Related]
5. Coverage of New Drugs in Medicare Part D.
Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
[TBL] [Abstract][Full Text] [Related]
6. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
Chambers JD; Pope EF; Wilkinson CL; Neumann PJ
J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201
[TBL] [Abstract][Full Text] [Related]
7. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
[TBL] [Abstract][Full Text] [Related]
8. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Panzer AD; Ingham M; Martin S; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
[No Abstract] [Full Text] [Related]
9. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
Neumann PJ; Crummer E; Chambers JD; Tunis SR
Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
[TBL] [Abstract][Full Text] [Related]
10. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
Robinson SW; Brantley K; Liow C; Teagarden JR
J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
[TBL] [Abstract][Full Text] [Related]
11. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
12. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.
Roginiel AC; Dhruva SS; Ross JS
Medicine (Baltimore); 2018 Oct; 97(40):e12715. PubMed ID: 30290675
[TBL] [Abstract][Full Text] [Related]
13. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.
Miguel A; Hall A; Liu W; Garrett J; Ballew A; Yang TH; Segal R
J Manag Care Spec Pharm; 2017 Jan; 23(1):13-21. PubMed ID: 28025924
[TBL] [Abstract][Full Text] [Related]
14. Patients' access to 2018 FDA-approved drugs 1 year post approval.
Panzer AD; Margaretos NM; Bridger N; Osani MC; Lai RC; Chambers JD
Am J Manag Care; 2022 Apr; 28(4):e153-e156. PubMed ID: 35420754
[TBL] [Abstract][Full Text] [Related]
15. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
[TBL] [Abstract][Full Text] [Related]
16. Medicare Part D-a roundtable discussion of current issues and trends.
Balfour DC; Evans S; Januska J; Lee HY; Lewis SJ; Nolan SR; Noga M; Stemple C; Thapar K
J Manag Care Pharm; 2009; 15(1 Suppl A):3-9. PubMed ID: 19125555
[TBL] [Abstract][Full Text] [Related]
17. Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain.
Chambers JD; May KE; Neumann PJ
Health Aff (Millwood); 2013 Jun; 32(6):1109-15. PubMed ID: 23733986
[TBL] [Abstract][Full Text] [Related]
18. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
[TBL] [Abstract][Full Text] [Related]
19. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
[TBL] [Abstract][Full Text] [Related]
20. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]